生物活性
SNX-2112是目前在临床试验中具有抗癌特性的热激蛋白90（Hsp90）抑制剂。SNX-2112通过Akt/mTOR/p70S6K抑制以时间和剂量依赖的方式诱导自噬。SNX-2112在人黑素瘤A-375细胞中诱导明显的凋亡和自噬，可能是有效的靶向治疗剂。
靶点信息
| HSP90α | HSP90β | | | |
| 30 nM(Ka) | 30 nM(Ka) | | | |
化学数据
| 目录号 | A11189 |
| 作用机制 | Inhibitor (抑制剂) |
| M. Wt | 464.48 |
| Formula | C23H27F3N4O3 |
| Purity | >99% |
| Storage | Store lyophilized at -20ºC, keep desiccated.
In lyophilized form, the chemical is stable for36 months.
In solution, store at -20ºC and use within3 monthsto prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles. |
| CAS No. | 908112-43-6 |
| Synonyms | SNX2112, PF 04928473 |
| SMILES | CC1(CC2=C(C(=O)C1)C(=NN2C3=CC(=C(C=C3)C(=O)N)NC4CCC(CC4)O)C(F)(F)F)C |
溶解度
| In vitro (25°C) | DMSO | 90 mg/mL (193.76 mM) |
| Water | Insoluble |
| Ethanol | 1 mg/mL (2.15 mM) |
| In vivo | 0.5% CMC+0.25% Tween 80 | 28 mg/mL |
*<1 mg/ml means slightly soluble or insoluble.
*Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
储备液配制
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
| 0.1 mM | 21.53 mL | 107.65 mL | 215.29 mL |
| 0.5 mM | 4.31 mL | 21.53 mL | 43.06 mL |
| 1 mM | 2.15 mL | 10.76 mL | 21.53 mL |
| 5 mM | 0.43 mL | 2.15 mL | 4.31 mL |
*The above data is based on the productmolecular weight 464.48. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
m.cnreagent.com